However, PHZ, an SGLT1/2 inhibitor, which ameliorates hyperglycemia without enhancing insulin secretion or action, fails to suppress HCC in STAM mice, suggesting that amelioration of hyperglycemia per se is insufficient to protect from HCC in STAM mice and in patients with diabetes and NASH. This evidence concerns the gene SLC5A1 and diabetes mellitus.